Bellerophon Therapeutics (NASDAQ:BLPH) Posts Earnings Results, Beats Expectations By $0.01 EPS

Bellerophon Therapeutics (NASDAQ:BLPH) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01, Fidelity Earnings reports.

Shares of BLPH traded down $0.02 during trading hours on Thursday, reaching $0.43. 46,200 shares of the company traded hands, compared to its average volume of 249,757. The stock has a market capitalization of $29.97 million, a P/E ratio of -1.26 and a beta of -0.05. The company has a quick ratio of 2.64, a current ratio of 2.64 and a debt-to-equity ratio of 0.15. Bellerophon Therapeutics has a 12-month low of $0.37 and a 12-month high of $1.22. The business has a fifty day moving average price of $0.48 and a 200-day moving average price of $0.59.

A number of equities research analysts have recently weighed in on BLPH shares. ValuEngine lowered shares of Bellerophon Therapeutics from a “hold” rating to a “sell” rating in a report on Monday. Maxim Group reissued a “buy” rating and set a $2.00 price objective on shares of Bellerophon Therapeutics in a report on Thursday.

In other Bellerophon Therapeutics news, major shareholder Associates Iv L. P. Venrock sold 704,595 shares of the company’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $0.50, for a total value of $352,297.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Associates Iv L. P. Venrock sold 333,010 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $0.44, for a total transaction of $146,524.40. The disclosure for this sale can be found here. 53.10% of the stock is owned by insiders.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

See Also: Market Timing

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.